® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,
1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13
th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. The findings will be simultaneously published in
The Lancet.
“This is the first randomized trial specific to metastatic papillary renal cell carcinoma to show a clinically and statistically significant benefit with a targeted therapy, CABOMETYX, over an existing standard of care,” said Dr. Sumanta Pal, Clinical Professor and Co-Director of the Kidney Cancer Program, City of H
Search jobs 08-Feb-2021
New data presented from NUBEQA
® (darolutamide) and Xofigo
® (radium Ra 223 dichloride) studies demonstrate Bayer’s continued commitment to ongoing prostate cancer research across different stages of the disease
Abstracts: 240, 239, 217, TPS266, 105, 135, TPS182, 48, 98, TPS175, 136
WHIPPANY, N.J. (BUSINESS WIRE) Bayer announced today that new NUBEQA
® (darolutamide) and Xofigo
® (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place from February 11-13, 2021. Among featured presentations are additional Phase III ARAMIS trial analyses evaluating the crossover effect from placebo to NUBEQA and safety follow-up in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Press release content from Business Wire. The AP news staff was not involved in its creation.
Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma
February 8, 2021 GMT
ALAMEDA, Calif. (BUSINESS WIRE) Feb 8, 2021
Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX ® (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC). The findings will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. All posters will be available on demand beginning at 5:00 a.m. PT on Thursday, February 11.
Sumitomo Dainippon Pharma Oncology Announces Phase 3 CanStem303C Study of Napabucasin Fails to Reach Primary Endpoints in Patients with Previously Treated Metastatic Colorectal Cancer
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 9, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS). Napabucasin in combination with FOLFIRI failed to show significant OS improvement in the general study population and in patients whose tumor was positive for the phosphorylated signal transducer and activator of transcription 3 (pSTAT3) biomarker.
Fresno, CA - A recent human study published in the
Journal of the American Academy of Dermatology found that consuming grapes protected against ultraviolet (UV) skin damage.
1 Study subjects showed increased resistance to sunburn and a reduction in markers of UV damage at the cellular level.
2 Natural components found in grapes known as polyphenols are thought to be responsible for these beneficial effects.
The study, conducted at the University of Alabama, Birmingham and led by principal investigator Craig Elmets, M.D., investigated the impact of consuming whole grape powder - equivalent to 2.25 cups of grapes per day - for 14 days against photodamage from UV light. Subjects skin response to UV light was measured before and after consuming grapes for two weeks by determining the threshold dose of UV radiation that induced visible reddening after 24 hours - the Minimal Erythema Dose (MED). Grape consumption was protective; more UV exposure was required to cause sunburn